We are live on ! Find out more
UNCY icon

Unicycive Therapeutics

12 hedge funds and large institutions have $1.48M invested in Unicycive Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more capital inflows, than outflows

Capital inflows: $127K | Capital outflows: $78.6K

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

9% more funds holding

Funds holding: 11 → 12 (+1)

0.24% more ownership

Funds ownership: 7.45% → 7.69% (+0.24%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

UNCY Hedge Fund Activity: Q1 2022 in Review

12 of the 6,366 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2022, worth a combined $1.48M — down 36% from $2.3M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new UNCY positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Truist Financial, opening a new position worth an estimated $54.9K. The largest seller was Nantahala Capital Management, cutting an estimated $67.6K.

  • 12 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2022, up from 11 in Q4 2021.
  • Funds reported $1.48M of Unicycive Therapeutics stock for Q1 2022, down 36% quarter-over-quarter.
  • 3 funds opened new Unicycive Therapeutics positions in Q1 2022 and 2 closed out, a net change of +1 holder.
  • The largest Unicycive Therapeutics buyer in Q1 2022 was Truist Financial, an estimated $54.9K added.
  • The largest Unicycive Therapeutics seller in Q1 2022 was Nantahala Capital Management, an estimated $67.6K sold.

Based on aggregated 13F filings for Q1 2022.